Larazotide
Also called AT-1001, INN-202
Oral (by mouth)Human study reference
Research reference
Human study
Larazotide celiac symptom trial
Separate 0.5, 1 and 2 mg groups, three times daily 15 minutes before meals
4-week placebo run-in → 12-week study course → 4-week placebo run-out
Leffler et al., Gastroenterology (2015) ↗When results may show
- When change was measured
- Weekly symptom scores were assessed over 12 weeks; the 0.5 mg group met the primary endpoint, higher groups did not.
- When to assess
- 4-week placebo run-in → 12-week study course → 4-week placebo run-out
- Conditions and limitations
- 342 adults with persistent symptoms despite a gluten-free diet. A study capsule is not an injection. This does not replace a gluten-free diet or establish a general gut-healing course.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Where these numbers come from
- Leffler et al., Gastroenterology (2015)A study capsule is not an injection. This does not replace a gluten-free diet or establish a general gut-healing course.